Abstract: A combined casting and rolling installation that produces hot-rolled strip with a final thickness<1.2 mm, and includes a first continuous casting installation and a second continuous casting installation, each producing slabs from liquid steel; a slab manipulator that conveys the slabs into a walking beam furnace that conveys the slabs into a rolling installation and heats the slabs to rolling temperature. The rolling installation includes a rough rolling mill forming rough-rolled strips from the heated slabs; a coil box forming a coil from the rough-rolled strip and unwinding the rough-rolled strip; a joining device forming an endless rough-rolled strip by connecting its ends without filler material; a multi-stand finishing rolling mill finish-rolling the endless rough-rolled strip to form a finished strip with the final thickness; a cooling section forming the hot-rolled strip; and a plurality of coiling devices coiling the hot-rolled strip.

Abstract: A threaded sleeve for assembling with heat input in a component manufactured by FDM process is provided. The threaded sleeve includes a groove along its longitudinal axis. Further, the outwardly facing surface of the threaded sleeve includes a self-tapping thread which is divided into two sections along the threaded sleeve's longitudinal axis. The first section includes a constant pitch diameter and the second area comprises a pitch diameter decreasing along its longitudinal axis. The inwardly facing surface of the threaded sleeve comprises a metric thread. Furthermore, a kit, a system and a method for assembling with heat input the above-mentioned threaded sleeve in a component manufactured by FDM process is provided.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of a neutral cellulosic compound and 1 to 25% by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.

Abstract: Thin indium-less “optically porous” layers adapted to replace traditional ITO layers are provided herein. A thin metalized film adapted to carry an electrical charge can include a dense pattern of small openings to allow the transmission of light to or from an underlying semiconductor material. The pattern of openings can create a regular or irregular grid pattern of low aspect ratio fine-line metal conductors. Creation of this optically porous metalized film can include the printing of a catalytic precursor material, such as palladium in solution in a pattern on a substrate, drying or curing the catalytic precursor, and the deposition of a thin layer of metal, such as copper on the dried precursor to form the final conductive and optically porous film.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40 95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5 60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250 % by weight of a non-porous inert lubricant, 1 to 35 % by weight of a neutral cellulosic compound and 1 to 25 % by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The hold-down device for a fuel injection device is distinguished by a particularly simple design that nonetheless permits a very effective holding down of a fuel injection valve. The fuel injection device includes at least one fuel injection valve, a receptacle bore for the fuel injection valve, and a connecting fitting of a fuel distributor line, the hold-down device being clamped between a shoulder of the fuel injection valve and an end surface of the connecting fitting. The hold-down device has a partially annular base element from which there extends, in a bent-away fashion, an axially flexible hold-down clip that has at least two webs, two oblique segments, and two support segments. The fuel injection valve is particularly suitable for use in fuel injection systems of mixture-compressing externally ignited internal combustion engines.

Abstract: The hold-down device for a fuel injection device is distinguished by a particularly simple design that nonetheless permits a very effective holding down of a fuel injection valve. The fuel injection device includes at least one fuel injection valve, a receptacle bore for the fuel injection valve, and a connecting fitting of a fuel distributor line, the hold-down device being clamped between a shoulder of the fuel injection valve and an end surface of the connecting fitting. The hold-down device has a partially annular base element from which there extends, in a bent-away fashion, an axially flexible hold-down clip that has at least two webs, two oblique segments, and two support segments. The fuel injection valve is particularly suitable for use in fuel injection systems of mixture-compressing externally ignited internal combustion engines.

Abstract: The invention relates to a dosage form, containing the active ingredient cholylsarcosine, in the form of pellets, which are provided with a polymer coating that is resistant to gastric juices. The invention is characterised in that it discloses pellets comprising an active ingredient, which contain between 50 and 80 wt. % of the active ingredient cholylsarcosine and between 50 and 20 wt. % of one or more conventional pharmaceutical adjuvants as binding agents, whereby at least 90 wt. % of said adjuvants are water-soluble and the size of at least 80 % of the pellets comprising an active ingredient is between 800 and 2,500 $g(m)m. The granulates containing an active ingredient are coated with an anonic, film-forming polymer coating agent, which dissolves in a 0.07M sodium phosphate buffer with a pH value of 5.5 at a dissolution rate of at least 10 mg/min*g and whose dissolution rate in a 0.07M sodium phosphate buffer with a pH value of 6.0 is at least 200 mg/min*g.

Abstract: A fuel injection system for injecting fuel into an internal combustion engine having at least one fuel injection valve, which has a fuel inlet orifice on an inlet section and having a fuel distribution line, which has, for each fuel injection valve a fuel outlet orifice that may be connected to the fuel inlet orifice of the fuel injection valve, and a connection fitting, connected downstream to the fuel outlet orifice. A connection arrangement injection valve to the respective fuel outlet orifice of the fuel distribution line is provided. The connection arrangement includes an annular seal support and a sleeve that can be inserted in the fuel inlet orifice. The annular seal support has a first sealing element for sealing the seal support against the inlet section of the fuel injection valve, and a second sealing element for sealing the seal support against the connection fitting of the fuel distribution line.